Figure 3.

Impact of programmed cell death‐1 ligand‐1 (PD‐L1) expression status and the tumor microenvironment on progression‐free survival (PFS) in patients with non‐small cell lung cancer after first‐line epidermal growth factor receptor‐ tyrosine kinase inhibitors (EGFR‐TKIs). A, Kaplan‐Meier curves for PFS in EGFR‐mutated NSCLC patients treated with first‐line EGFR‐TKIs, according to PD‐L1 expression. B, Comparison of the Kaplan‐Meier curves for PFS after first‐line EGFR‐TKIs, according to the tumor microenvironment subtype (Type 1‐4). Plus signs denote censoring. C, Swimmer plot shows duration of first‐line EGFR‐TKIs treatment for patients on this study. CI, confidence interval; TIL, tumor‐infiltrating lymphocyte